Skip to content ↓

MIT-affiliated companies take on Covid-19

A variety of companies with MIT ties are working to address aspects of the Covid-19 pandemic.
Watch Video
Listen
Press Inquiries

Press Contact:

Abby Abazorius
Phone: 617-253-2709
MIT News Office

Media Download

From developing vaccines to helping governments keep communities informed, a number of companies with MIT ties are working to address problems brought on by the Covid-19 pandemic.
Download Image
Caption: From developing vaccines to helping governments keep communities informed, a number of companies with MIT ties are working to address problems brought on by the Covid-19 pandemic.
Credits: Image: CDC; Christine Daniloff, MIT

*Terms of Use:

Images for download on the MIT News office website are made available to non-commercial entities, press and the general public under a Creative Commons Attribution Non-Commercial No Derivatives license. You may not alter the images provided, other than to crop them to size. A credit line must be used when reproducing images; if one is not provided below, credit the images to "MIT."

Close
From developing vaccines to helping governments keep communities informed, a number of companies with MIT ties are working to address problems brought on by the Covid-19 pandemic.
Caption:
From developing vaccines to helping governments keep communities informed, a number of companies with MIT ties are working to address problems brought on by the Covid-19 pandemic.
Credits:
Image: CDC; Christine Daniloff, MIT

As the world grapples with the public health crises and myriad disruptions brought on by the Covid-19 pandemic, many efforts to address its impact are underway.

Several of those initiatives are being led by companies that were founded by MIT alumni, professors, students, and researchers.

These companies’ efforts are as wide ranging and complex as the challenges brought on by Covid-19. They leverage expertise in biological engineering, mobile technology, data analytics, community engagement, and other fields MIT has long focused on.

The companies, a few of whom are featured here, are also at very different stages of deployment, but they are all driven by a desire to use science, engineering, and entrepreneurship to solve the world’s most pressing problems.

Moderna Therapeutics

On Jan. 11, Chinese authorities shared the genetic sequence of Covid-19. Just two days later, members of a research team from Moderna Therapeutics, in collaboration with the National Institutes of Health, finalized the design of a vaccine they hope will prevent infection from the disease.

Moderna was founded by Institute Professor Robert Langer, who is also a faculty member at the Institute for Medical Engineering and Sciences (IMES), investor Noubar Afeyan PhD ’87, and researchers from Harvard Medical School in 2010. The company develops treatments that leverage specialized transporter molecules in cells known as messenger RNAs. Messenger RNAs bring instructions from genes to the cellular machinery that makes proteins. By creating specially modified mRNA, Moderna believes it can develop therapies to treat and prevent a number of diseases in humans.

Following its design of a potential Covid-19 vaccine, the company quickly moved to manufacture the mRNA vaccine for clinical trials. On March 16, just 65 days after Covid-19 was sequenced, Moderna began human trials, according to the company.

The first stage of the trials is expected to last six weeks and will focus on the safety of the vaccine as well as the immune response it provokes in participants. The company has said that while a commercially available vaccine is not likely to be available for at least 12-18 months, it is possible that under emergency use, a vaccine could be available to some people sooner.

Alnylam Pharmaceuticals

On March 5, Alnylam Pharmaceuticals announced that its partnership with Vir Biotechnology, which focuses on treating infectious diseases, would extend to developing therapeutics for coronavirus infections, including Covid-19.

Alnylam was founded in 2002 by Institute Professor Phil Sharp, who is also a faculty member at the Institute for Medical Engineering and Sciences (IMES), Professor David Bartel, former MIT professor Paul Schimmel, MIT postdocs Tom Tuschl and Phil Zamore, and investors.

The company is already approved to treat patients with certain rare genetic diseases using its patented RNA interference technology. RNA interference, or RNAi, is a method of stopping the expression of specific genes through the manipulation of existing regulatory processes in the human body.

“[RNAi] technology is now strongly validated in a variety of ways and the promise of it is really remarkable,” says Sharp, who currently sits on Alnylam’s scientific advisory board with Bartel and Schimmel. “It’s the creation of a whole new therapeutic modality that I think we’ll be using 100 years from now.”

Under the terms of the extended collaboration, the companies will use Alnylam’s recent advances in delivering its RNAi technology to the lungs, in addition to Vir’s infectious disease capabilities, to identify and advance drug candidates.

Sharp says that even if the collaboration doesn’t lead to a treatment for the current Covid-19 outbreak, it holds tremendous potential for helping victims of infectious diseases down the line.

Dimagi

Dimagi, which provides a platform for creating mobile apps that can be used offline by cell phones of all types, recently began freely offering its mobile tool to organizations responding to the Covid-19 outbreak around the world.

The company’s platform is currently being used by hundreds of thousands of front-line health care workers globally. By enabling people with no coding experience to create mobile apps that work in environments with no cellular service, the company has transformed health care treatment for millions of people in low- and middle-income countries.

The company has already seen governments adopt its platform for Covid-19 response, including the Ogun state government of Nigeria, and it is also exploring use cases with officials from the U.S. Centers for Disease Control and Prevention in California.

The company was formed in 2002 when Jonathan Jackson’03 SM ’05 met co-founder Vikram Kumar, who was then a graduate research assistant in MIT’s Media Lab and on his way to earning his MD in the MIT-Harvard Division of Health Sciences and Technology.

Since then, Dimagi’s solutions have been used for a variety of large health care initiatives, including the Ebola crisis in West Africa, where the company worked directly with health organizations to give them mobile applications that helped provide critical care during their Ebola response.

Jackson believes Dimagi can help health care workers with tracking person-to-person contact, data collection, decision support, and spreading useful information. The company is also compiling a library of free, open-source templated Covid-19 mobile applications for quick deploymnent.

“Think of it as a free app store where health organizations working on the front lines can go, download their Covid-19 applications and quickly equip their health workforces with Covid-19 apps,” Jackson says.

Biobot Analytics

Biobot Analytics, a startup that analyzes wastewater to gain insights into public health, has begun requesting sewage samples from wastewater treatment facilities across the U.S. to test for SARS-CoV-2, the virus causing Covid-19.

The company’s technology, developed by CEO Mariana Matus PhD ’18 during her time at MIT in partnership with Newsha Ghaeli, then a research fellow in the Department of Urban Studies and Planning, has been geared toward estimating drug consumption in communities since its founding in 2017.

Biobot uses a proprietary device to gather representative samples of sewage, then ships those samples to its scientists for near-real time testing. Samples can be used to track opioid use, nutrition, environmental contaminants, antibiotic resistance, and the spread of infectious diseases. The resulting insights can be used to understand the health and well-being of small communities or large cities.

In the company’s Covid-19 testing program, which it launched pro bono in collaboration with researchers at MIT, Harvard, and Brigham and Women’s Hospital, the teams will process sewage samples from treatment facilities across the U.S., then use a laboratory technique known as a reverse transcription polymerase chain reaction to determine the presence of SARS-CoV-2.

The collaborators believe the program could complement existing testing methods in addition to helping guide community reponses, measure the effectiveness of interventions, and provide an early warning for re-emergence of the outbreak.

“There is an incredible opportunity to use this technology to get ahead of and monitor the Covid-19 epidemic,” the company wrote in a recent Medium post announcing the program. “A wastewater epidemiology system that aggregates samples from wastewater treatment plants across the U.S. would provide a dynamic map of Covid-19 as it spreads to new places. [This will be a tracker for the outbreak complementary to individual testing]. Government officials, school administrators, and employers would no longer need to rely on confirmed cases or hospital reporting to make tough decisions like enforcing work from home policies.”

Soofa

Soofa, a startup that creates solar-powered digital signs in public spaces, has begun offering its city partners templates to quickly post emergency announcements regarding Covid-19. In Massachusetts, the templates have been used in Brookline to post updates about school and playground closures, in Somerville to redirect people to the town’s coronavirus webpage, and in Everett, which has posted their updates in both English and Spanish to reach more people.

Soofa was founded in 2014 by Jutta Friedrichs and Sandra Richter, a former researcher in MIT’s Media Lab. The founders refer to their signs as “neighborhood news feeds” because they offer an easy, inclusive way for community members to view and post messages.

The company’s digital signage has also proven useful for its partners outside of government. Boston Architectural College, for example, now gives viewers instructions to attend their spring virtual open house.

Pathr

Pathr is a startup that uses data analytics and machine learning to understand how people move through environments. The company, which has primarily used its technology to help retailers, casino operators, and owners of public spaces gain insights into customer behavior, recently launched a new product called SocialDistance.ai.

SocialDistance.ai will use Pathr’s “spatial intelligence” platform to give operators of large spaces information on how infectious diseases might spread in different scenarios.

Pathr's platform can be used to simulate the spread of infectious diseases in different scenarios. In this video playlist, simulations incorporating measures such as social distancing (second video) and mask distribution (third video) are shown.

SocialDistance.ai was formed when Pathr’s team got locked down in the San Francisco Bay Area, where the company is based, and began thinking about how their technology could help address disruptions related to the Covid-19 outbreak.

“There’s a spatial component to disease outbreak in general, and we’ve been hearing a lot about that with this coronavirus, so that was the spark, just thinking about what we could do to help,” says Pathr founder and CEO George Shaw SM ’11.

Shaw says his team has been in touch with officials who run malls, casinos, retail stores, and various public spaces to help them make more informed decisions about allowing people to use their spaces in the time periods surrounding an outbreak.

“Nobody who operates a big space wants to limit the number of people [in that space], so this would be a way to strike that balance, to get the right social distance, the right density of crowds; it could also help owners reconfigure a space so the flow of people is more conducive to social distancing,” Shaw says.

Shaw developed the spatial intelligence platform as a graduate student in the lab of Professor Deb Roy while working on a project in the Media Lab.

Press Mentions

Bloomberg Businessweek

Bloomberg Businessweek reporter Nick Leiber spotlights how Biobot Analytics, an MIT startup, is analyzing sewage in municipalities around the country to estimate the number of people with Covid-19 in a particular area. Our vision is for this to be deployed across the tens of thousands of wastewater facilities in the U.S.,” explains Biobot Analytics president and co-founder Newsha Ghaeli.

The Wall Street Journal

Prof. Eric Alm speaks with Wall Street Journal reporter David Winning about how wastewater could be used to help track the spread of Covid-19. “The flu is pretty tricky to test in wastewater,” says Alm. “For Covid-19, we’re fortunate that it is excreted in large enough amounts.”

Boston Globe

Boston Globe reporter David Abel writes that researchers from MIT, Biobot Analytics (an MIT startup) and other institutions have found that samples from wastewater treatment plants could provide insights into the spread of Covid-19 in specific areas.

Forbes

Forbes contributor Katie Jennings writes that Biobot Analytics, an MIT startup, is examining wastewater to gauge the scope of Covid-19 infections. “We see this technology as being an infrastructure layer that is embedded permanently into our wastewater systems in order to alert us as an early warning,” explains Biobot Anlytics President and co-founder Newsha Ghaeli, “whether it's COVID, or whether it's something else.”

Boston 25 News

MIT startup Biobot Analytics is analyzing wastewater as part of an effort to better understand the spread of Covid-19, reports Boston 25. Mariana Matus, CEO and co-founder of Biobot Analytics, explains that, “Our objective is to make this data available to all of our leaders, our decision-makers…so they have the best data available to open cities in a smart way.”

WGBH

WGBH reporter Daniel Ackerman spotlights how MIT startup BioBot Analytics, along with researchers from MIT and other institutions, are sampling wastewater to try to gain a better understanding of the prevalence of Covid-19 in specific communities. Ackerman notes that “Biobot’s sewage sampling could help them craft guidelines for public health protections like social distancing.”

Newsweek

Newsweek reporter Aristos Georgiou writes that researchers from MIT, BioBot Analytics (an MIT startup) and other institutions have found more traces of the coronavirus in wastewater samples than anticipated given confirmed cases. “Having accurate estimates of disease prevalence will help cities plan for what kind of resources they will need when disease prevalence hits its peak,” explains Prof. Eric Alm.

Stat

A team of researchers from MIT, BioBot Analytics (an MIT startup), and other institutions found evidence in wastewater that were likely more people infected with Covid-19 than the reported cases in that area, reports Shraddha Chakradhar for STAT. Chakradhar notes that, “wastewater sampling could offer a community-level picture of how the disease has spread.”

ABC News

ABC News contributor Dr. Nancy Anoruo spotlights BioBot, an MIT startup that uses wastewater to track the spread of disease. "We hope to use this kind of data to stop outbreaks before they reach epidemic levels so we will never find ourselves again in a situation like we are in today,” explains Prof. Eric Alm.

Related Links

Related Topics

Related Articles

More MIT News